Machine Learning Can Identify Immune Markers for Better Pneumococcal Vaccines

With the help of artificial intelligence (AI) and machine learning, it was found that protein-based vaccines with multiple antigens can provide greater protection against pneumococcal diseases, regardless of serotype distribution, according to Vaccine.¹

“While the speed and scale of COVID-19 vaccine development have demonstrated the promise of AI in modern immunology, this acceleration resulted from multiple convergent factors: massive funding, preexisting mRNA platforms, overlapping trial phases, and global collaboration—not solely from AI,” wrote the authors of a study published in Frontiers in Immunology.² “Nevertheless, AI-based methods—from rapid epitope mapping to adaptive clinical trial designs—have helped shorten certain phases from years to months, illustrating a potential paradigm shift in how vaccines are conceived, tested, and produced.”

This paradigm shift is particularly evident among recently reported data, which address a persistent challenge in pneumococcal prevention, such as the limitations of current serotype-specific vaccines. Although existing pneumococcal conjugate vaccines (PCVs) have significantly reduced disease, they only protect against a fraction of the more than 100 known serotypes.³

This has led to the phenomenon of serotype replacement, where nonvaccine types fill the ecological niche left by targeted strains. Even broad-spectrum pipeline vaccines, such as the 31-valent PCV, are still bound by the constraints of capsular polysaccharide targets.^1,3

READ MORE: Capvaxive Receives Additional Indication for High-Risk Children 2 to 17

To break this cycle, researchers utilized a controlled human infection model and applied the Random Forest machine learning algorithm to identify protein antigens that remain conserved across all serotypes.¹

The investigation revealed that protection against pneumococcal colonization is not the result of a single immune marker but rather a coordinated, multi-antigen response. By analyzing high-dimensional datasets, the machine learning models identified IgG responses to specific proteins, including PdB, SP1069, and SP0899, as critical predictors of protection.

Furthermore, cellular models showed that certain cytokine responses, specifically MCP-1 and IL-17A, were associated with reduced susceptibility. For pharmacists, these findings represent the blueprint for a universal pneumococcal vaccine that could simplify immunization schedules and eliminate the need for frequent reformulations as serotype distribution shifts.^1,3

This trend toward AI-driven antigen design is gaining momentum across the field of immunology. At the University of Cambridge, researchers recently achieved a milestone by using AI to design a super-antigen for a fundamentally new type of vaccine.⁴

Unlike traditional methods that use current viral strains, this AI analyzed the genetic codes of a whole family of viruses to create a vaccine that provides protection even against mutated variants. This capability to get ahead of the curve is a transformative leap that mirrors the identification of conserved pneumococcal proteins.^1,4

An umbrella review of AI in vaccine development further supports this, noting that deep learning architectures and multi-omic integration have already shrunk discovery timelines from years to months.²

However, the discovery of a better vaccine is only half the battle. Ensuring patient acceptance is the next frontier for AI in the health care system. Pharmacists play a role in this arena, and AI is increasingly being used to optimize vaccine delivery and combat hesitancy.^2,5

Innovative predictive models, such as those utilizing the LightGBM algorithm, have demonstrated the ability to forecast vaccine acceptance with 98% accuracy. By analyzing demographic and sociodemographic factors, these models allow providers to identify high-risk groups and design tailored interventions.⁵

Complementing these predictive tools are real-time engagement platforms like hybrid AI chatbots. Recent studies have shown that these chatbots can significantly boost pneumococcal vaccination rates among older adults by providing personalized, evidence-based conversations that address specific concerns in real-time.⁶

For the pharmacy profession, these AI-driven innovations offer the development of more effective, serotype-independent vaccines and the technological tools to ensure those vaccines reach the most vulnerable populations.^1,2,6

As machine learning continues to refine our understanding of immune markers, the goal of achieving broad, lasting protection against pneumococcal disease moves closer to reality.^1,3,4

“As immunology and vaccinology increasingly rely on complex, high-dimensional datasets, predictive computational models offer substantial advantages over traditional analyses by uncovering intricate relationships between immune responses and protection,” concluded authors of the current study.¹ “The integration of advanced computational approaches with human challenge models, which uniquely allow sampling immediately before and after defined pathogen exposure, promises to transform how we define protective immunity and accelerate rational vaccine design.”

READ MORE: Pneumococcal Resource Center

REFERENCES

1. Cheliotis KS, Gonzalez-Dias P, German EL, et al. Machine learning-driven identification of serotype-independent pneumococcal vaccine candidates using samples from human infection challenge studies. Vaccine. 2026;75:128280. https://doi.org/10.1016/j.vaccine.2026.128280

2. El Arab RA, Alkhunaizi M, Alhashem YN, et al. Artificial intelligence in vaccine research and development: an umbrella review. Front Immunol. 2025 May 8;16:1567116. doi: 10.3389/fimmu.2025.1567116.

3. King LM, Andrejko KL, Kobayashi M, et al. Pneumococcal serotype distribution and coverage of existing and pipeline pneumococcal vaccines. J Infect Dis. 2025 Oct 15;232(4):e609-e620. doi: 10.1093/infdis/jiaf376.

4. Gallagher J. “World-first” vaccine designed by artificial intelligence. BBC. June 4, 2026. Accessed June 24, 2026. https://www.bbc.com/news/articles/crrpggegwe0o

5. Qureshi MS, Qureshi MB, Iqrar U, et al. AI based predictive acceptability model for effective vaccine delivery in healthcare systems. Sci Rep. 2024 Nov 4;14(1):26657. doi: 10.1038/s41598-024-76891-z. Erratum in: Sci Rep. 2025 Jan 28;15(1):3578. doi: 10.1038/s41598-024-85096-3.

6. Nowosielski B. AI chatbot could significantly boost pneumococcal vaccine rates. Drug Topics. December 8, 2025. Accessed June 24, 2026. https://www.drugtopics.com/view/ai-chatbot-could-significantly-boost-pneumococcal-vaccine-rates